TECH OUTLOOK 6JUNE - 2022TECH OUTLOOKEditorialStacey Smith Editor-in-Chiefeditor@pharmatechoutlook.comWith a growing need for faster time-to-market, the pharma industry is on the verge of a disruptive transformation. The increasing prevalence of chronic diseases has also raised the global demand for effective therapies, which calls for quality healthcare products. Moreover, the successful management of pharmaceutical enterprises revolves around the discovery, development, testing, manufacturing, and marketing of new drugs. And individually overseeing each task becomes daunting as businesses and the overall market evolve and expand after the pandemic. Discovering and developing drugs is crucial for the growth of any pharmaceutical company. Therefore, employing a contract manufacturing organization (CMO) to manage the development and manufacturing of a drug significantly improves revenue generation and other bottom-line operations.By the end of 2021, the CMO industry was valued at $134.12 billion, a figure that is predicted to reach $204.14 billion by 2027, expanding at a CAGR of 6.64 percent. The biggest factor influencing the pharma arena's shift toward adopting CMOs is the need for cutting-edge processes and production technologies that are proven to support pharma businesses in consistently meeting the ever-growing regulatory requirements. A key example of this heightened significance of outsourced manufacturing is the movement toward injectable media, which is driving numerous pharma firms to acquire injectable manufacturing companies and expand their production competencies.In this edition of Pharma Tech Outlook, we bring you some of the most promising contract manufacturing organizations that deliver the best outcomes for their clients. This edition also combines thought leadership from subject matter experts for aspiring CIOs and CXOs in the pharma sector. We hope this edition provides you with the right assistance in choosing the best contract manufacturing organization according to your requirements.Fuelling Pharmaceutical Companies with Innovative CMOsCopyright © 2022 ValleyMedia, Inc. All rights reserved. Reproduction in whole or part of any text, photography or illustrations without written permission from the publisher is prohibited. The publisher assumes no responsibility for unsolicited manuscripts, photographs or illustrations. Views and opinions expressed in this publication are not necessarily those of the magazine and accordingly, no liability is assumed by the publisher thereof.JUNE - 06 - 2022, Vol 08 - Issue 03 (ISSN 2644-2787) Published by ValleyMedia, Inc. To subscribe to Pharma Tech OutlookVisit www.pharmatechoutlook.com Disclaimer: *Some of the Insights are based on our interviews with CIOs and CXOsEditor-in-ChiefStacey SmithVisualizerPresley MeadowEditorial StaffAaron Pierce Ava GarciaJenna VegasCarolynn Walters Justin SmithPaul BarberSalesBrian Thomasbrian@pharmatechoutlook.comPhone: 510.556.2402sales@pharmatechoutlook.comeditor@pharmatechoutlook.commarketing@pharmatechoutlook.comEmail:Contact Us:Phone:510.556.2402, TECH OUTLOOK
< Page 5 | Page 7 >